Gainers

• Bullfrog AI Hldgs (NASDAQ:BFRG) stock rose 15.2% to $1.21 during Monday's after-market session. The market value of their outstanding shares is at $6.4 million.
• Coherus Oncology (NASDAQ:CHRS) stock increased by 9.99% to $1.76. The market value of their outstanding shares is at $244.3 million.
• ABVC BioPharma (NASDAQ:ABVC) shares rose 9.96% to $1.0. The market value of their outstanding shares is at $25.4 million.
• Invivyd (NASDAQ:IVVD) stock increased by 9.15% to $1.3. The company's market cap stands at $386.3 million.
• Jasper Therapeutics (NASDAQ:JSPR) shares rose 8.88% to $0.98. The company's market cap stands at $29.3 million. The company's, Q4 earnings came out today.
• Kodiak Sciences (NASDAQ:KOD) stock moved upwards by 7.73% to $36.27. The company's market cap stands at $2.2 billion.

Losers

• PepGen (NASDAQ:PEPG) shares decreased by 44.5% to $2.35 during Monday's after-market session. The company's market cap stands at $310.7 million.
• Phreesia (NYSE:PHR) stock decreased by 19.81% to $9.15. The company's market cap stands at $661.9 million. As per the news, the Q4 earnings report came out today.
• Sangamo Therapeutics (NASDAQ:SGMO) stock fell 14.84% to $0.26. The company's market cap stands at $119.2 million. As per the news, the Q4 earnings report came out today.
• iTonic Holdings (NASDAQ:ITOC) shares declined by 9.83% to $0.37. The market value of their outstanding shares is at $6.7 million.
• China SXT Pharmaceuticals (NASDAQ:SXTC) shares decreased by 8.49% to $1.51. The market value of their outstanding shares is at $1.1 million.
• Lunai Bioworks (NASDAQ:LNAI) shares decreased by 7.83% to $0.38. The company's market cap stands at $9.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.